Type 2 diabetes remission: economic evaluation of the DiRECT/Counterweight‐Plus weight management programme within a primary care randomized controlled trial

Xin, Y. , Davies, A., McCombie, L., Briggs, A. , Messow, C.-M. , Grieve, E. , Leslie, W.S., Taylor, R. and Lean, M.E.J. (2019) Type 2 diabetes remission: economic evaluation of the DiRECT/Counterweight‐Plus weight management programme within a primary care randomized controlled trial. Diabetic Medicine, 36(8), pp. 1003-1012. (doi:10.1111/dme.13981) (PMID:31026353)

[img] Text
185885.pdf - Accepted Version
Restricted to Repository staff only until 26 April 2020.

686kB

Abstract

Aim: The Counterweight‐Plus weight management programme achieved 46% remission of Type 2 diabetes at 1 year in the DiRECT trial. We estimated the implementation costs of the Counterweight‐Plus programme and its 1‐year cost‐effectiveness in terms of diabetes remission, compared with usual care, from the UK National Health Service (NHS) perspective. Methods: Within‐trial total costs included programme set‐up and running costs (practitioner appointment visits, low‐energy formula diet sachets and training), oral anti‐diabetes and anti‐hypertensive medications, and healthcare contacts. Total costs were calculated for aggregated resource use for each participant and 95% confidence intervals (CI) were based on 1000 non‐parametric bootstrap iterations. Results: One‐year programme costs under trial conditions were estimated at £1137 per participant (95% CI £1071, £1205). The intervention led to a significant cost‐saving of £120 (95% CI £78, £163) for the oral anti‐diabetes drugs and £14 (95% CI £7.9, £22) for anti‐hypertensive medications compared with the control. Deducting the cost‐savings of all healthcare contacts from the intervention cost resulted an incremental cost of £982 (95% CI £732, £1258). Cost per 1 year of diabetes remission was £2359 (95% CI £1668, £3250). Conclusions: Remission of Type 2 diabetes within 1‐year can be achieved at a cost below the annual cost of diabetes (including complications). Providing a reasonable proportion of remissions can be maintained over time, with multiple medical gains expected, as well as immediate social benefits, there is a case for shifting resources within diabetes care budgets to offer support for people with Type 2 diabetes to attempt remission. (Clinical Trial Registry No.: ISRCTN03267836).

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Xin, Miss Yiqiao and Grieve, Miss Eleanor and Messow, Dr Martina and Lean, Professor Michael and Davies, Mr Andrew and Leslie, Dr Wilma and Briggs, Professor Andrew
Authors: Xin, Y., Davies, A., McCombie, L., Briggs, A., Messow, C.-M., Grieve, E., Leslie, W.S., Taylor, R., and Lean, M.E.J.
College/School:College of Medical Veterinary and Life Sciences > Institute of Health and Wellbeing > Health Economics and Health Technology Assessment
College of Medical Veterinary and Life Sciences > Institute of Health and Wellbeing > Robertson Centre
College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing
Journal Name:Diabetic Medicine
Publisher:Wiley
ISSN:0742-3071
ISSN (Online):1464-5491
Published Online:26 April 2019
Copyright Holders:Copyright © 2019 Diabetes UK
First Published:First published in Diabetic Medicine 36(8): 1003-1012
Publisher Policy:Reproduced in accordance with the publisher copyright policy

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
614614Reversal of T2DM to normal glucose tolerance using non-surgical weight management with low-energy liquid- diet and long-term maintenance, within routine NHS care: study extensionMichael LeanDiabetes UK (DIABETUK)13/0004691MVLS MED -HUMAN NUTRITION
3007920Economic Evaluation of the Diabetes Remission Clinical Trial DiRECTMichael LeanDiabetes UK (DIABETUK)17/0005695Med - Human Nutrition

Downloads per month over past year

View more statistics